RHON-KLINIKUM AG

As of June 30, 2026, RHON-KLINIKUM AG carries a market capitalization of 856.81M, placing it among publicly traded companies globally. Its enterprise value stands at 330.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

RHON-KLINIKUM AG's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, RHON-KLINIKUM AG has 66.94M shares outstanding.

As of June 30, 2026, RHON-KLINIKUM AG trades at a trailing price-to-earnings ratio of 20.18. The price-to-sales ratio is 0.49, and the price-to-book ratio stands at 0.64.

As of June 30, 2026, RHON-KLINIKUM AG trades at an EV/EBITDA multiple of 2.84 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.48 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 330.68M versus a market cap of 856.81M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, RHON-KLINIKUM AG maintains a current ratio of 2.63, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, RHON-KLINIKUM AG posted a return on equity (ROE) of 3.20, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.02 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.28, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.16, useful for judging operating efficiency across full business cycles. The company generates approximately 91,150.01 in revenue per employee across its workforce of 19,032.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 31.48 indicates how many times RHON-KLINIKUM AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, RHON-KLINIKUM AG recorded 10.83M in income tax expense. That works out to an effective tax rate of 19.73, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 54.91M, leaving 42.09M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, RHON-KLINIKUM AG's stock has gained approximately 24.35% over the past 52 weeks. The 50-day moving average sits at 14.43, while the 200-day moving average is 13.15.

Over the twelve months ended June 30, 2026, RHON-KLINIKUM AG generated 1.73B in revenue and converted that into 42.09M in net income, yielding earnings per share of 0.66. EBITDA reached 116.27M, while operating income came in at 40.30M.

These figures are as of June 30, 2026. Total book value stands at 1.33B, with working capital of 562.01M providing operational flexibility.

Over the twelve months ended June 30, 2026, RHON-KLINIKUM AG posted a gross margin of 27.89, reflecting its pricing power and cost economics. The operating margin of 2.32 and net profit margin of 2.43 provide insight into operational efficiency.

RHON-KLINIKUM AG's most recent stock split took place on July 22, 2009 with a 30:31 split ratio.